Tianjin Medical University Cancer Institute & Hospital
Research
Cen
ter for C
ancer N
ano
techn
olo
gy
Tianjin Medical University Cancer Institute & Hospital
Research
Cen
ter for C
ancer N
ano
techn
olo
gy
A Promising Chemotherapy Agent, Gd@C82(OH)22
Ning ZhangTianjin Medical University Cancer Institute and Hospital
UICC 2008
Tianjin Medical University Cancer Institute & Hospital
Research
Cen
ter for C
ancer N
ano
techn
olo
gy
Tianjin Medical University Cancer Institute & Hospital
Research
Cen
ter for C
ancer N
ano
techn
olo
gy
Chemotherapies have always been
accompanied with serious side effects.
Can nanoparticles provide a new approach to
design low toxic therapeutic agents?
Tianjin Medical University Cancer Institute & Hospital
Research
Cen
ter for C
ancer N
ano
techn
olo
gy
Tianjin Medical University Cancer Institute & Hospital
Research
Cen
ter for C
ancer N
ano
techn
olo
gy
Treatments with Gd@C82(OH)22 Inhibit hepatoma growth in a mouse model
Nano Lett Vol 5, pg 2050 Gd@C82(OH)22 inhibits tumor growth in a breast tumor model.
0.28 mg/kg1.20mg/kg
Tianjin Medical University Cancer Institute & Hospital
Research
Cen
ter for C
ancer N
ano
techn
olo
gy
Tianjin Medical University Cancer Institute & Hospital
Research
Cen
ter for C
ancer N
ano
techn
olo
gy
Gd@C82(OH)22 doesn’t show cytotoxicity
Tianjin Medical University Cancer Institute & Hospital
Research
Cen
ter for C
ancer N
ano
techn
olo
gy
Tianjin Medical University Cancer Institute & Hospital
Research
Cen
ter for C
ancer N
ano
techn
olo
gy
Treatments with Gd@C82(OH)22 reduced blood supply to tumors
Tianjin Medical University Cancer Institute & Hospital
Research
Cen
ter for C
ancer N
ano
techn
olo
gy
Tianjin Medical University Cancer Institute & Hospital
Research
Cen
ter for C
ancer N
ano
techn
olo
gy
Treatments with Gd@C82(OH)22 reduced blood vessel density
Tianjin Medical University Cancer Institute & Hospital
Research
Cen
ter for C
ancer N
ano
techn
olo
gy
Tianjin Medical University Cancer Institute & Hospital
Research
Cen
ter for C
ancer N
ano
techn
olo
gy
Treatments with Gd@C82(OH)22 induced a massive leukocyte infiltration in tumors.
Tianjin Medical University Cancer Institute & Hospital
Research
Cen
ter for C
ancer N
ano
techn
olo
gy
Tianjin Medical University Cancer Institute & Hospital
Research
Cen
ter for C
ancer N
ano
techn
olo
gy
Gd@C82(OH)22 induced iDC maturation and TH-1 response.
Tianjin Medical University Cancer Institute & Hospital
Research
Cen
ter for C
ancer N
ano
techn
olo
gy
Tianjin Medical University Cancer Institute & Hospital
Research
Cen
ter for C
ancer N
ano
techn
olo
gy
TreatmentsMetastasis
Rate
Salineq.d. ×20 day
66.7%
C60(C(COOH)2)2
(0.4 mg/kg, n = 10)
34.2%
C60(OH)20 (0.4
mg/kg, n = 10)38.0%
Gd@C82(OH)22 ,0.35mg/kg
q.d. ×20 day4.3 %
Treatments with Gd@C82(OH)22 cancer cell chemotaxis and metastasis
Tianjin Medical University Cancer Institute & Hospital
Research
Cen
ter for C
ancer N
ano
techn
olo
gy
Tianjin Medical University Cancer Institute & Hospital
Research
Cen
ter for C
ancer N
ano
techn
olo
gy
Summary
1. Treatment with Gd@C82(OH)22 inhibits tumor growth without detectable toxicity.
2. Gd@C82(OH)22 doesn’t show cytotoxicity.
3. Gd@C82(OH)22 inhibits blood supply to tumor tissues.
4. Gd@C82(OH)22 induced tumor immunity.
5. Gd@C82(OH)22 inhibits cancer cell chemotaxis
Blood supply
Tumor immunity
Metastasis
Tianjin Medical University Cancer Institute & Hospital
Research
Cen
ter for C
ancer N
ano
techn
olo
gy
Tianjin Medical University Cancer Institute & Hospital
Research
Cen
ter for C
ancer N
ano
techn
olo
gy
Chinese AcademyInstitute of High Energy
Physics
Tianjin Cancer Institute and
Hospital
Research Center for Cancer Nanotechnology
National Center of Nanotechnology
Tianjin Medical University Cancer Institute & Hospital
Research
Cen
ter for C
ancer N
ano
techn
olo
gy
Tianjin Medical University Cancer Institute & Hospital
Research
Cen
ter for C
ancer N
ano
techn
olo
gy
Acknowledgements
Nanosafety Lab, Chinese Academy of ScienceDr. Yuliang Zhao, DirectorDr. Gengmei XingHuan Meng
Laboratory of Molecular Immunoregulation, NCIDr. Joost Oppenheim, ChiefDr. De Yang
Dr. Yujie MaDr. Guoguang YingDr. Ruifang Niu
Tianjin Medical University Cancer Institute & Hospital
Research
Cen
ter for C
ancer N
ano
techn
olo
gy
Tianjin Medical University Cancer Institute & Hospital
Research
Cen
ter for C
ancer N
ano
techn
olo
gy
Gd@C82(OH)22 induced a dendritic cell maturation
Tianjin Medical University Cancer Institute & Hospital
Research
Cen
ter for C
ancer N
ano
techn
olo
gy
Tianjin Medical University Cancer Institute & Hospital
Research
Cen
ter for C
ancer N
ano
techn
olo
gy
HR (100 ug/ml)-treated DCs migrated to SLC but not Rantes, suggesting the HR-treated DCs were mature DCs.
Gd@C82(OH)22 induced a dendritic cell to express CCR7 receptors
Tianjin Medical University Cancer Institute & Hospital
Research
Cen
ter for C
ancer N
ano
techn
olo
gy
Tianjin Medical University Cancer Institute & Hospital
Research
Cen
ter for C
ancer N
ano
techn
olo
gy
T cell cytokine production in response to Gd@C82(OH)22 -treated DCs
Tianjin Medical University Cancer Institute & Hospital
Research
Cen
ter for C
ancer N
ano
techn
olo
gy
Tianjin Medical University Cancer Institute & Hospital
Research
Cen
ter for C
ancer N
ano
techn
olo
gy
Treatments with Gd@C82(OH)22 disrupted the integrity of capillary blood vessels in tumors.